relapsed/refractory large B-cell lymphoma. relapsed/refractory large B-cell lymphoma.
Conditions
Interventions
None listed
Sponsors
Teshima Takanori
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)18 years of age or older at the time of enrollment (2)Patients who meet the indications specified in Guidelines for the Promotion of Optimal Use, axicabtagene ciloleucel (Ref. 1). (3)Patents who are scheduled to receive axi-cel at the participating medical institutions in this study (prospective observational study) (4)Patients who have already received axi-cel administration at a medical institution participating in this study* (retrospective observational study) (5)Patients who have given their free and voluntary consent to participate in this study or patients who do not refuse to participate in the study.
Exclusion criteria
Exclusion criteria: Patients deemed inappropriate as study subjects by the principal investigator in participating medical institution (hereafter referred to as the "site principal investigator"
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate at 6 months after axi-cel administration (overall response, complete response, partial response) | — |
Contacts
Public ContactHideki Goto
Hokkaido University Hospital
Outcome results
None listed